{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"57"}],"units":"Participants"}],"description":"Treatment-emergent (post-dose) positive elotuzumab-specific ADA is differentiated from pre-existing (positive at the predose time point) positive elotuzumab-specific ADA. The percentage of participants with confirmed treatment-emergent ADA overall by dose is provided.","groups":[{"description":"Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG000","title":"Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG001","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG002","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study drug and with at least one evaluable post-dose sample.","reportingStatus":"POSTED","timeFrame":"From screening through 60-day follow up period (up to 101 months)","title":"Percentage of Participants With Treatment-emergent Anti-elotuzumab Antibody (ADA)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}